Find insight on Abbott Laboratories, Sartorius and more in the latest Market Talks covering the Health Care sector.

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.

Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease. This authorisation makes the amyloid-beta (Aβ) ...

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy in the EU to slow the progression of early Alzheimer’s disease.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (A?) monoclonal antibody Leqembi® ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

Nvidia Corp. Chief Executive Jensen Huang didn’t exactly please Wall Street at the so-called Super Bowl of AI. But now he’s giving President Donald Trump credit for his company’s new ...

Royalty Pharma (RPRX) announced the appointment of Vlad Coric to the company’s board of directors, effective immediately. Vlad Coric is the ...

Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.